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The Editorial on the Research Topic
Biomarkers of Alzheimer’s Disease: The Present and the Future
iNtrodUCtioN
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive 
deficits, behavioral changes, sleep disorders, and loss of functional autonomy. The number of 
patients suffering from AD is growing rapidly as the population ages worldwide. AD represents 
the major cause of dementia and has become a major public health issue. Memory impairment 
is usually the earliest but also the core symptom of this disease. The diagnosis at a late stage is 
relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms 
of optimal medical and social care. Moreover, early diagnosis is essential to start treatments, which 
are conceivably more effective at the prodromal stage. The actual interest of the scientific head-ways 
is therefore to optimize the diagnosis in prodromal stage of the disease and to propose personalized 
therapeutic solutions to individual patients. New revised AD diagnostic criteria include alteration 
of cerebrospinal fluid (CSF) biomarkers: a decrease in concentrations of amyloid peptides (Aβ42) 
and an increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of 
CSF biological biomarkers for diagnosis of AD is a major step toward the “molecular” diagnosis and 
follow-up of the disease. However, many issues are still subject of debate and further developments 
in this field focus on:
 – First of all, there is a large debate on the appropriate and optimal use of the current CSF amyloid 
and tau biomarkers that now face clinical implementation – when and how (alone or in combina-
tion) to use them: for AD screening, in routine, for early or atypical AD cases, etc.
 – How to measure them in the most reliable way? A question that necessitates discussion on 
standard operating procedures, harmonization, quality control, establishment of reference mate-
rial and methods, and comparison of analytical platforms (immunoassays, single and multiplex 
assays, and mass spectrometry).
 – The use of biomarkers (and in particular Aβ42) for the stratification, the follow-up and to predict 
therapeutic responses of patients involved in therapeutic trials targeting AD pathology.
 – How to improve the biological diagnosis of AD (in terms of sensitivity, specificity, or differen-
tiation from other neurodegenerative disorders) with the help of new biomarkers? This major 
topic has two complementary aspects: the detection of additional Aβ and tau isoforms and the 
detection of completely new biomarkers (in particular from “omics” studies). Of note, there is not 
a week without the suggestion in the literature of a new putative biomarker for AD.
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 – Related to the above item, is the issue of a blood diagnosis of 
AD. As a matter of fact, validated AD biomarkers are currently 
detected only in the CSF, which limits their usage in screen-
ing or monitoring patients. The standardization of blood 
 collection/assays for putative AD biomarkers is however 
far from the position of the CSF field, and it will need to be 
addressed specifically.
 – The last but not the least important issue of current and new 
biomarkers is how they relate to the understanding of the 
pathophysiology of AD and to new therapeutic leads.
The articles of this research topic address most of the issues 
listed above. Chapter 1 addresses the use of the current biomark-
ers of AD, i.e., amyloid and tau related. Bros et  al. focus on 
the analysis of tau using mass spectrometry as a way to detect 
and quantify specific tau isoforms, and Struyfs et  al. describe 
the added value of pTau for differential diagnosis of dementia 
subtypes. Dorey et  al. focus on the use of Aβ40 in a ratio to 
Aβ42, which is currently a hot topic in the field, demonstrating 
that it improves the interpretation of Aβ42 for the diagnosis 
of AD. Several diagnostic centers apply this ratio on a routine 
basis, while other centers are not yet using it. Will this paper 
provide the final verdict? The next two papers of this chapter 
focus on amyloid-related biomarkers, i.e., anti-amyloid antibod-
ies and amyloid oligomers. The anti-amyloid antibodies could be 
useful tools to detect ARIA’s as reported in the contribution of 
DiFrancesco. ARIA’s are a threatening side effect of anti-amyloid 
therapies and thus important to detect early during treatment. 
Oligomers are promising biomarkers but suffer from their versa-
tility: oligomers are unstable under physiological and laboratory 
conditions, which is problematical to control. A stable standard 
for quantification of oligomers in biomarker assays is needed 
and Kühbach et  al. describe the performance of their newly 
developed standard. The last two papers of this chapter by Ritter 
and Blennow give an excellent view of the current state of the 
art on biomarker developments for clinical trials and dementia 
diagnosis.
Papers in the chapter 2 of the research topic address meth-
odological and quality issues during analysis. The major part of 
the papers is the result of the activities of a strong international 
network within the 3-year duration of the joint programming for 
neurodegenerative diseases project, “BIOMARKAPD” (http://
biomarkapd.org/). BIOMARKAPD aimed to standardize all 
aspects of the assessment of established and new fluid biomark-
ers for AD and Parkinson’s disease (PD). This was driven by 
the fact that large variation in biomarker measurements were 
reported between studies, both between and within centers. 
Such variations may be caused by pre-analytical, analytical, or 
assay-related factors. They seriously jeopardize the introduction 
of biomarkers in clinical routine and trials around the world. 
The BIOMARKAPD consortium has established a virtual and a 
central biobank that are open for use for biomarker research, as 
presented in the first article of this chapter by Reijs et al. Biobanks 
containing body fluids of well-characterized patient cohorts are 
an invaluable source for biomarker development and validation 
studies. The next two papers by Leitão et  al. and Cicognola 
et  al. address the influence of pre-analytical confounders on 
CSF biomarker results, including sample handling (centrifuga-
tion speed and temperature) and diurnal variation. Two of the 
important guidelines developed by the BIOMARKAPD project 
are also published in this chapter: Andreasson et al. present a 
practical guide for immunoassay validation. There was a lack 
of such a practical guide, though such a guideline would help 
uniform validation of novel biomarker tests for use in clinical 
practice. Moreover, this guideline increases the awareness of 
the importance of assay validation before implementation in 
research settings and clinical routine. The paper of Del Campo 
et al. next describes an optimal workflow for cost-effective bio-
marker immunoassay development. Researchers that perform 
biomarker identification studies, e.g., by proteomics, often 
need to develop novel immunoassays for their novel candidate 
biomarkers, with limited resources. Del Campo et al. describe a 
systematic and rational workflow to optimize the cost-effective 
development of such assays. Then, Galasko addresses the 
development of novel biomarker candidates using the omics 
approaches by giving a critical review of the progress and 
results obtained this far. Finally, the review by Schindler and 
Fagan emphasizes the important information of the pathology 
or trajectories of biomarkers that were obtained by studying 
biomarkers in families with dominant inherited Alzheimer’s 
diseases, which is an incredible precious cohort.
In the last two chapters, which focus on CSF and blood 
biomarkers, the different articles by Steen Jensen, Paquet, 
Lopez-Font, Zhao, Herbert, Inekci, Delaby, Fiandaca, and Baird 
propose new biomarkers such as plasma proteins of amyloid 
pathology, miRNA, cytokines, kinases, axonal proteins, lipids, 
and fragments of already known markers. These articles give 
valuable insight into the novel approaches which could result in 
the identification of biomarkers useful in the field of diagnosis 
or therapeutic trials.
In conclusion, the topic “Biomarkers of Alzheimer’s disease” 
is a very active topic that has a major importance for medical 
diagnosis, basic research, and therapeutics in the neurology and 
neuroscience field. CSF biomarkers are increasingly implemented 
in clinical routine to sustain the diagnosis of dementias knowing 
that there is a strong need for accurate, sensitive, and reliable 
biomarkers for AD. This will in fact help early diagnosis, targeted 
therapeutics, prognosis, and follow-up of patients. We are pleased 
that the current research topic gives a comprehensive state of the 
art of the use of the biomarkers, and projects good faith into the 
implementation of well-validated novel biomarkers for dementia 
in the future.
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